{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:42:10Z","timestamp":1699490530525},"reference-count":11,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Migraine remains one of the most disabling disorders worldwide. The high prevalence in the general population and the often-delicate treatment of patients account for that. Therapeutic management of migraine relies mainly on non-specific medical treatment and is affected by low patient adherence to the treatment regimens applied. The introduction of specific anti-migraine treatment occurred over 20 years ago when the first triptan was approved by regulatory authorities (sumatriptan, 28 December 1992). Triptan use is limited by side effects, time- and frequency-restricted application, and the risk of developing medication overuse headache. Within the past few years, new and promising drugs such as more specific 5-HT 1F receptor agonists (that is, lasmiditan) and monoclonal calcitonin gene-related peptide (CGRP) receptor antibodies entered advanced development phases while non-invasive neuromodulatory approaches were suggested to be potentially effective as non-pharmaceutical interventions for migraine.<\/ns4:p>","DOI":"10.12688\/f1000research.9764.1","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T12:16:52Z","timestamp":1479730612000},"page":"2726","update-policy":"http:\/\/dx.doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Recent advances in the management of migraine"],"prefix":"10.12688","volume":"5","author":[{"given":"Mark","family":"Obermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagny","family":"Holle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"2163-96","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010.","volume":"380","author":"T Vos","year":"2012","journal-title":"Lancet."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"703-11","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project.","volume":"19","author":"M Linde","year":"2012","journal-title":"Eur J Neurol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"46-54","DOI":"10.1177\/1756285614562419","article-title":"The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.","volume":"8","author":"U Reuter","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"ref-4","article-title":"CoLucid Pharmaceuticals Announces Achievement of Secondary Endpoints in SAMURAI","year":"2016"},{"key":"ref-5","first-page":"1417-18","article-title":"AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor.","volume":"54","author":"L Shi","year":"2014","journal-title":"Headache."},{"key":"ref-6","first-page":"5","article-title":"Results of a randomized, double-blind, placebo controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine.","volume":"35","author":"R Lenz","year":"2015","journal-title":"Cephalalgia."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1100-7","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.","volume":"13","author":"D Dodick","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"885-92","DOI":"10.1016\/S1474-4422(14)70128-0","article-title":"Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.","volume":"13","author":"D Dodick","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1081-90","DOI":"10.1016\/S1474-4422(15)00249-5","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.","volume":"14","author":"M Bigal","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1091-100","DOI":"10.1016\/S1474-4422(15)00245-8","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.","volume":"14","author":"M Bigal","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"529-38","DOI":"10.1212\/WNL.0000000000002918","article-title":"Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.","volume":"87","author":"S Silberstein","year":"2016","journal-title":"Neurology."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:27:25Z","timestamp":1553254045000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":11,"URL":"https:\/\/doi.org\/10.12688\/f1000research.9764.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.10526.r17739","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.10526.r17740","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.10526.r17738","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.10526.r17739, Joost Haan, Alrijne Ziekenhuis, Leiden, The Netherlands, 21 Nov 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1#referee-response-17739","order":0,"name":"referee-response-17739","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.10526.r17738, Kevin C. Brennan, Department of Neurology, University of Utah, Salt Lake City, UT, USA, 21 Nov 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1#referee-response-17738","order":1,"name":"referee-response-17738","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.10526.r17740, Hanns Ulrich Zeilhofer, Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland, 21 Nov 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-2726\/v1#referee-response-17740","order":2,"name":"referee-response-17740","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"MO received research grants from Allergan, Electrocore, Heel, and the German Ministry for Education and Research (BMBF). DH received research grants from Allergan, Electrocore, and the BMBF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}